Subsequent to quarter end, a Sponsored Research Agreement was...

Subsequent to quarter end, a Sponsored Research Agreement was executed with Massachusetts General Hospital with Dr. Matthew Rosen as Principal Investigator. The Sponsored Research Agreement will leverage the Center’s extensive magnetic resonance imaging and spectroscopy facilities to characterize Imagion’s super paramagnetic iron oxide nanoparticles and evaluate if they can be optimized for use in vascular, or other MR imaging applications, as an alternative to GBCA’s.). Dr. Rosen directs the Low-Field MRI and Hyperpolarized Media Laboratory at the A.A. Martinos Center and is a leader in low and ultra-low field MRI.

While the Company’s MagSense® technology aims to use targeted magnetic nanoparticles to detect specific types of diseased tissue, such as cancers, the purpose of this research is to evaluate the potential to leverage the Company’s underlying expertise with magnetic nanoparticles to develop a non-targeted imaging agent as aid in diagnostic imaging of cardiovascular diseases